TP53 and cancer: However, to achieve their therapeutic fruitions, most ADCs rely on the expression of clinically relevant cancer biomarkers such as CSPG4, whose co-expression with the well characterized programmed death-ligand-1 (PDL-1: immune checkpoint inhibitor) in 25% of TNBC patients bearing TP53 mutation, has been associated with poor prognosis, treatment response, and overall survival, respectively (Hu et al. 2022).